

Nobuo Okabe,* Yasunori
Muranishi and Mamiko OdokoFaculty of Pharmaceutical Sciences, Kinki
University, Kowakae 3-4-1, Higashiosaka,
Osaka 577-8502, JapanCorrespondence e-mail:
okabe@phar.kindai.ac.jp

Key indicators

Single-crystal X-ray study
 $T = 296$ K
Mean $\sigma(\text{C}-\text{C}) = 0.005$ Å
 R factor = 0.027
 wR factor = 0.075
Data-to-parameter ratio = 16.6For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.**(1,1-Cyclobutanedicarboxylato- $\kappa^2\text{O},\text{O}'$)-
(2,2'-biquinoline- $\kappa^2\text{N},\text{N}'$)palladium(II)
monohydrate**

In the title compound, $[\text{Pd}(\text{C}_6\text{H}_6\text{O}_4)(\text{C}_{18}\text{H}_{12}\text{N}_2)] \cdot \text{H}_2\text{O}$, the Pd^{II} atom has a distorted *cis*-planar four-coordination geometry defined by two O atoms of a bidentate 1,1-cyclobutanedicarboxylate anion and two N atoms of the 2,2'-biquinoline ligand. In the crystal structure, centrosymmetric clusters of the complex molecules and water molecules are formed through $\text{O}-\text{H} \cdots \text{O}$ hydrogen bonds.


Received 14 September 2005

Accepted 19 September 2005

Online 21 September 2005

Comment

cis-Square-planar coordinated Pt^{II} complexes such as cisplatin [*cis*-diamminedichloroplatinum(II)], carboplatin [*cis*-diammine(1,1-cyclobutanedicarboxylato)platinum(II)] and oxaliplatin [*trans*-1-1,2-diaminocyclohexane platinum(II) oxalate], are well known anticancer drugs. Carboplatin with a bidentate 1,1-cyclobutanedicarboxylato (cbdca) ligand has fewer side effects than cisplatin (Jakupec *et al.*, 2003). Pd^{II} analogues of Pt^{II} complexes have been used as good models for studies of the chemistry of square planar complexes (Rau & van Eldik, 1996). For example, *cis*-diammine(1,1-cyclobutanedicarboxylate)palladium(II) (Barnham *et al.*, 1994) is isostructural with carboplatin (Beagley *et al.*, 1985; Neidle *et al.*, 1980). Recently, the palladium complex with the aromatic heterocyclic ligand $[\text{Pd}(\text{bpy})(\text{cbdca})]$ (bpy = 2,2'-bipyridine) has been shown to have better cytotoxic activity than cisplatin against P_{388} lymphocytic leukemia cells (Mansuri-Torshizi *et al.*, 2001). Aromatic heterocycles can stack with nucleobases and enhance complex formation with DNA, which is the principal target in the chemotherapy of tumors (Shehata, 2001).



In a previous study (Muranishi & Okabe, 2004), we determined the structures of the carboplatin analogs of Pd^{II} complexes with *N,N'*-bidentate aromatic heterocycle ligands bipyridine(bpy), $[\text{Pd}(\text{bpy})(\text{cbdca})]$, and 1,10-phenanthroline (phen), $[\text{Pd}(\text{phen})(\text{cbdca})] \cdot \text{H}_2\text{O}$ and $[\text{Pd}(\text{phen})(\text{cbdca})] \cdot 2\text{H}_2\text{O}$. Because biq (biq = 2,2'-biquinoline) is an aromatic heterocyclic compound with interesting characteristics, such as




Figure 1
Molecular structure of (I), with the atom numbering scheme. Displacement ellipsoids are drawn at the 50% probability level.

inhibition activity against the formation of an abnormal prion protein (Murakami-Kubo *et al.*, 2004) and mutagenic activity as the rhodamin(III) complex (Sadiq & Zaghaf, 1996), we present in this study the structure of $[\text{Pd}(\text{biq})(\text{cbdca})]\cdot\text{H}_2\text{O}$, (I).

The central Pd atom of (I) has a distorted *cis*-square planar coordination geometry, from two N atoms of biq and two O atoms of the cbdca ligand (Fig. 1). The overall structure of (I) resembles those of $[\text{Pd}(\text{bpy})(\text{cbdca})]$, (II), $[\text{Pd}(\text{phen})(\text{cbdca})]\cdot\text{H}_2\text{O}$, (IIIa), and $[\text{Pd}(\text{phen})(\text{cbdca})]\cdot 2\text{H}_2\text{O}$, (IIIb) (Muranishi & Okabe, 2004). The bond lengths and bond angles in (I) are similar to those in (II), (IIIa) and (IIIb) and selected values are compared in Table 2. The Pd atom makes a six-membered chelate ring with cbdca in a boat conformation, and a five-membered chelate ring with biq in an envelope conformation, in which the deviation of atom Pd1 from the N1/C2/C12/N12 plane is 0.671 (4) Å. The biq group is non-planar, with a dihedral angle of 20.5 (1)° between the two quinoline ring systems. The cyclobutane least-squares plane is almost perpendicular to the N1–C2–C12–N12 plane in biq, with a dihedral angle of 86.8 (2)°.

The N–Pd–N chelate angle in (I), as well as in (II), (IIIa) and (IIIb), is smaller than those in the ethylenediamine (en) ligand in $[\text{Pd}(\text{en})(\text{cbdca})]$ [84.15 (8)°; Tercero *et al.*, 2003] or the NH_3 ligand in $[\text{Pd}(\text{NH}_3)_2(\text{cbdca})]$ [95.0°; Barnham *et al.*, 1994]. In the crystal structure, centrosymmetric clusters of the title complex and water molecules are formed through O–H...O hydrogen bonds (Table 1).

Experimental

Biq (5.0 mg) dissolved in dimethylformamide (DMF, 2 ml) was reacted with palladium acetate, $[\text{Pd}(\text{CH}_3\text{COOH})_2]$ (4.4 mg), dissolved in DMF (2 ml) for 15 min at room temperature (molar ratio of 1:1), and then an equimolar amount of 1,1-cyclobutanedicarboxylic acid dissolved in DMF (1 ml) was added with stirring. This mixture was left to stand at room temperature, and yellow block-like crystals appeared in a few days.

Crystal data

$[\text{Pd}(\text{C}_6\text{H}_6\text{O}_4)(\text{C}_{18}\text{H}_{12}\text{N}_2)]\cdot\text{H}_2\text{O}$
 $M_r = 522.84$
 Triclinic, $P\bar{1}$
 $a = 10.363$ (2) Å
 $b = 10.438$ (2) Å
 $c = 11.450$ (2) Å
 $\alpha = 64.66$ (1)°
 $\beta = 80.87$ (2)°
 $\gamma = 69.07$ (1)°
 $V = 1045.5$ (4) Å³

$Z = 2$
 $D_x = 1.661$ Mg m⁻³
 Mo $K\alpha$ radiation
 Cell parameters from 25 reflections
 $\theta = 14.9$ – 15.0 °
 $\mu = 0.93$ mm⁻¹
 $T = 296.2$ K
 Block, yellow
 $0.35 \times 0.15 \times 0.10$ mm

Data collection

Rigaku AFC-5R diffractometer
 ω - 2θ scans
 Absorption correction: ψ scan
 (North *et al.*, 1968)
 $T_{\min} = 0.846$, $T_{\max} = 0.911$
 5074 measured reflections
 4809 independent reflections
 4179 reflections with $I > 2\sigma(I)$

$R_{\text{int}} = 0.025$
 $\theta_{\text{max}} = 27.5$ °
 $h = -13 \rightarrow 12$
 $k = -13 \rightarrow 0$
 $l = -14 \rightarrow 13$
 3 standard reflections
 every 150 reflections
 intensity decay: 0.9%

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.027$
 $wR(F^2) = 0.075$
 $S = 1.22$
 4809 reflections
 289 parameters
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.1P)^2]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} = -0.001$
 $\Delta\rho_{\text{max}} = 0.32$ e Å⁻³
 $\Delta\rho_{\text{min}} = -0.44$ e Å⁻³
 Extinction correction: *SHELXL97*
 Extinction coefficient: 0.0000

Table 1

Hydrogen-bond geometry (Å, °).

| <i>D</i> –H... <i>A</i> | <i>D</i> –H | H... <i>A</i> | <i>D</i> ... <i>A</i> | <i>D</i> –H... <i>A</i> |
|--------------------------|-------------|---------------|-----------------------|-------------------------|
| O5–H5A...O4 | 0.90 | 2.07 | 2.958 (4) | 169 |
| O5–H5B...O2 ⁱ | 0.96 | 1.85 | 2.794 (6) | 166 |

Symmetry code: (i) $-x + 1, -y + 1, -z + 1$.

Table 2

Comparative selected geometric parameters (Å, °).

| | (I) | (II) ⁱ | (IIIa) ⁱ | (IIIb) ⁱ |
|-----------|------------|-------------------|---------------------|---------------------|
| Pd1–O1 | 1.995 (2) | 2.002 (2) | 2.003 (4) | 2.001 (3) |
| Pd1–O3 | 1.988 (3) | 2.004 (2) | 2.005 (4) | 1.982 (3) |
| Pd1–N1 | 2.037 (3) | 1.999 (2) | 1.991 (5) | 2.002 (4) |
| Pd1–N2 | 2.020 (2) | 1.998 (2) | 1.994 (5) | 2.010 (4) |
| O1–Pd1–O3 | 88.20 (8) | 91.68 (7) | 91.3 (2) | 92.8 (1) |
| O1–Pd1–N1 | 96.49 (9) | 93.94 (8) | 93.0 (2) | 93.3 (1) |
| O1–Pd1–N2 | 171.53 (9) | 174.40 (6) | 173.2 (2) | 174.7 (1) |
| O3–Pd1–N1 | 168.17 (8) | 174.37 (9) | 174.7 (2) | 172.7 (2) |
| O3–Pd1–N2 | 93.51 (9) | 93.57 (8) | 93.2 (2) | 91.6 (1) |
| N1–Pd1–N2 | 80.31 (9) | 80.80 (8) | 82.2 (2) | 82.1 (1) |

Note: (i) From Muranishi & Okabe (2004).

All H atoms were located in difference Fourier maps, and were then treated as riding with C–H = 0.93 and 0.97 Å, and $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$. The H atoms of the water molecule were located in a difference Fourier map but their parameters were not refined.

Data collection: *MSC/AFC Diffractometer Control Software* (Molecular Structure Corporation, 1992); cell refinement: *MSC/AFC Diffractometer Control Software*; data reduction: *TEXSAN* (Molecular Structure Corporation, 2000); program(s) used to solve structure: *SIR97* (Altomare *et al.*, 1999); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPII* (Johnson, 1976); software used to prepare material for publication: *TEXSAN* (Molecular Structure Corporation, 2000).

References

- Altomare, A., Burla, M. C., Camalli, M., Cascarano, G. L., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). *J. Appl. Cryst.* **32**, 115–119.
- Barnham, K. J., Djuran, M. I., Frey, U., Mazid, M. A. & Sadler, P. J. (1994). *J. Chem. Soc. Chem. Commun.* pp. 65–66.
- Beagley, B., Cruickshank, D. W. J., McAuliffe, C. A., Pritchard, R. G., Zaki, A. M., Beddoes, R. L., Cernik, R. J. & Mills, O. S. (1985). *J. Mol. Struct.* **130**, 97–102.
- Jakupec, M. A., Galanski, M. & Keooler, B. K. (2003). *Rev. Physiol. Biochem. Pharmacol.* **146**, 1–53.
- Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
- Mansuri-Torshizi, H., Ghadimy, S. & Akbarzadeh, N. (2001). *Chem. Pharm. Bull.* **49**, 1517–1520.
- Molecular Structure Corporation (1992). *MSC/AFC Diffractometer Control Software*. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.
- Molecular Structure Corporation (2000). *TEXSAN*. Version 1.11. MSC, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.
- Murakami-Kubo, I., Doh-ura, K., Ishikawa, K., Kawatake, S., Sasaki, K., Kira, J., Ohta, S. & Iwaki, T. (2004). *J. Virol.* **78**, 1281–1288.
- Muranishi, Y. & Okabe, N. (2004). *Acta Cryst.* **C60**, m47–m50.
- Neidle, S., Ismail, I. M. & Sadler, P. J. (1980). *J. Inorg. Biochem.* **13**, 205–212.
- North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
- Rau, T. & van Eldik, R. (1996). *Metal Ions in Biological Systems*, Vol. 32, edited by A. Sigel & M. Sigel, pp. 339–378. New York: Marcel Dekker.
- Sadiq, M. F. & Zaghal, M. H. (1996). *Polyhedron*, **16**, 1483–1486.
- Shehata, M. (2001). *Transition Met. Chem.* **26**, 198–204.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Tercero, J. M., Matilla, A., Sanjuan, M. A., Moreno, C. F., Martin, J. D. & Walmsley, J. A. (2003). *Inorg. Chem. Acta*, **342**, 77–87.